Inactive Instrument

Highlights Opiant Pharmaceuticals, Inc.

Equities

OPNT

US6837501039

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Indivior completes acquisition of Opiant Pharmaceuticals	23-03-02	AN
Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals	23-03-02	MT
Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc. from a group of shareholders.	23-03-01	CI
Indivior Wins US Regulatory Nod To Acquire Opiant Pharmaceuticals	23-02-07	MT
Indivior announces expiry of waiting period for Opiant purchase	23-02-06	AN
Opiant Pharmaceuticals Says Waiting Period Expires for Proposed Takeover by Indivior Expires	23-02-06	MT
Indivior Nears Acquisition of Opiant Pharmaceuticals	23-02-06	MT
Opiant Pharmaceuticals Granted FDA Priority Review for Opioid Overdose Therapy	23-01-20	MT
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose	23-01-19	CI
Opiant Pharmaceuticals Completes Rolling Submission of New Drug Application for Potential Opioid Overdose Drug	22-11-23	MT
Opiant Pharmaceuticals, Inc. Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose	22-11-22	CI
Indivior buys Opiant creating "comprehensive" treatment platform	22-11-14	AN
Opiant Pharmaceuticals to Be Acquired by Indivior	22-11-14	MT
Indivior to Acquire Opiant Pharmaceuticals For Initial $145 Million Consideration	22-11-14	MT
Opiant Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Indivior PLC entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. from a group of shareholders for approximately $110 million.	22-11-13	CI
Opiant Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder	22-10-06	CI
Opiant Pharmaceuticals Gets US Patent Allowance for OPNT004 to Treat Cannabinoid Hyperemesis Syndrome	22-08-22	MT
Earnings Flash (OPNT) OPIANT PHARMACEUTICALS Reports Q2 Revenue $3.9M, vs. Street Est of $4.66M	22-08-11	MT
Opiant Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Opiant Pharmaceuticals, Inc.

Equities

OPNT

US6837501039

Highlights

Filters